Ridhima Aggarwal

Ridhima Aggarwal

Auto-generated profile, based on publicly available information

Ridhima Aggarwal

University College London Great Ormond Street Institute of Child Health 1 , London

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2023 in Asia Pacific Allergy
Verified
Journal Article
Open access
AJAnkur Kumar Jindal
Ankur Kumar Jindal
ASArchan Sil
Archan Sil
RARidhima Aggarwal
Ridhima Aggarwal
KVKeshavamurthy Vinay
Keshavamurthy Vinay
ABAnuradha Bishnoi
Anuradha Bishnoi
SDSunil Dogra
Sunil Dogra
Hereditary angioedema (HAE) is an uncommon disorder characterized clinically by recurrent episodes of nonitchy subcutaneous and/or submucosal swellings. The estimated prevalence of HAE is ~ 1: 10,000 to 1: 50,000. There are no prevalence data from India, however, estimates suggest that there are 27,000 to 135,000 patients with HAE in India at present. The majority of these, however, remain undiagnosed. Replacement of plasma-derived or recombinant C1-esterase inhibitor (C1-INH) protein, administered intravenously, is the treatment of choice during the management of acute episodes of angioedema (i.e., “on-demand treatment”) and is also useful for short-term prophylaxis (STP) and long-term prophylaxis (LTP). This has been found to be effective and safe even in young children and during pregnancy. Until recently, none of the first-line treatment options were available for “on-demand treatment,” STP or LTP in India. As a result, physicians had to use fresh frozen plasma for both “on-demand treatment” and STP. For LTP, attenuated androgens (danazol or stanozolol) and/or tranexamic acid were commonly used. These drugs have been reported to be useful for LTP but are associated with a significant risk of adverse effects. Intravenous pd-C1-INH, the first-line treatment option, is now available in India. However, because there is no universal health insurance, access to pd-C1-INH is a significant challenge. HAE Society of India has developed these consensus guidelines for India and other resource-constrained settings where plasma-derived C1-INH therapy is the only available first-line treatment option for the management of HAE and diagnostic facilities are limited. These guidelines have been developed because it may not be possible for all patients to access the recommended therapy and at the recommended doses as suggested by the international guidelines. Moreover, it may not be feasible to follow the evaluation algorithm suggested by the international guidelines.

18 September 2023 in Journal of Clinical Immunology
Verified
Journal Article
Closed access
PDF file
PVPandiarajan Vignesh
Pandiarajan Vignesh
ASArchan Sil
Archan Sil
RARidhima Aggarwal
Ridhima Aggarwal
WLWrik Laha
Wrik Laha
SMSanjib Mondal
Sanjib Mondal
SSSurjit Singh
Surjit Singh

26 May 2026
Verified
Journal Article
Open access
DSDeepti Suri
Deepti Suri
PNPallavi L. Nadig
Pallavi L. Nadig
DDDev Desai
Dev Desai
YSYamini Sharma
Yamini Sharma
AJAhmed Jamal
Ahmed Jamal
SSSurjit K. Singh
Surjit K. Singh
Suri et al. from PGIMER, Chandigarh, India, report large vessel vasculopathy as a rare, life-threatening, and underrecognized complication of Wiskott–Aldrich syndrome, often mimicking Takayasu arteritis. They implicate immune dysregulation, endothelial injury, and viral triggers, emphasizing early vascular screening and timely definitive therapy to reduce high mortality.

30 September 2026 in Journal of Human Immunity
Verified
Journal Article
Open access
RARidhima Aggarwal
Ridhima Aggarwal
AMAlison Mansfield
Alison Mansfield
JXJinhua Xu-Bayford
Jinhua Xu-Bayford
CBClaire Booth
Claire Booth
KVKonstantinos Vazouras
Konstantinos Vazouras
We describe two cases of ADA-SCID complicated by hepatoblastoma and infantile hepatic hemangiomatosis. We highlight the multidisciplinary management of these severe liver manifestations and the modifications required to deliver definitive corrective therapy, including gene therapy and hematopoietic stem cell transplantation.